No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage
-
Boronic Acids / adverse effects
-
Bortezomib
-
Creatinine / blood
-
Dehydration / etiology
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Kidney Failure, Chronic / blood
-
Kidney Failure, Chronic / etiology
-
Male
-
Middle Aged
-
Multiple Myeloma / blood
-
Multiple Myeloma / complications
-
Multiple Myeloma / drug therapy*
-
Pyrazines / administration & dosage
-
Pyrazines / adverse effects
-
Recurrence
-
Remission Induction
-
Resveratrol
-
Salvage Therapy*
-
Stilbenes / administration & dosage
-
Stilbenes / adverse effects
-
Treatment Failure
-
Vomiting / chemically induced
-
Vomiting / complications
Substances
-
Boronic Acids
-
Pyrazines
-
Stilbenes
-
Bortezomib
-
Creatinine
-
Resveratrol
Associated data
-
ClinicalTrials.gov/NCT00920556